Pedro Barata, MD, University Hospitals Seidman Cancer Center, Cleveland, OH, describes novel agents for the management of castration-resistant prostate cancer (CRPC), including an anti-PSCA CAR T-cell therapy, which was assessed in a Phase I trial (NCT03873805). Additional developments include a Phase I trial (NCT04886986) of 225Ac-J591, an alpha-radiolabeled antibody, and 177Lu-PSMA I&T, a beta-radioligand, in patients with metastatic CRPC. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
